Loading...

BIOREM

TSXV:BRM
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BRM
TSXV
CA$15M
Market Cap
  1. Home
  2. CA
  3. Commercial Services
Company description

BIOREM Inc., an environmental biotechnology company, designs, manufactures, and sells air emissions control systems that are used to eliminate odors, volatile organic compounds, and hazardous air pollutants in Canada, the United States, China, and internationally. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
BRM Share Price and Events
7 Day Returns
0%
TSXV:BRM
-1.1%
CA Commercial Services
0.8%
CA Market
1 Year Returns
5.3%
TSXV:BRM
-19.2%
CA Commercial Services
3.9%
CA Market
BRM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BIOREM (BRM) 0% 0% 8.1% 5.3% 37.9% 48.1%
CA Commercial Services -1.1% -0% -5.4% -19.2% 0.3% -49%
CA Market 0.8% 2.3% 7.9% 3.9% 15.4% 7.5%
1 Year Return vs Industry and Market
  • BRM outperformed the Commercial Services industry which returned -19.2% over the past year.
  • BRM outperformed the Market in Canada which returned 3.9% over the past year.
Price Volatility
BRM
Industry
5yr Volatility vs Market

Value

 Is BIOREM undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BIOREM. This is due to cash flow or dividend data being unavailable. The share price is CA$0.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BIOREM's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BIOREM's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:BRM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$0.12
TSXV:BRM Share Price ** TSXV (2019-04-18) in CAD CA$0.4
Canada Commercial Services Industry PE Ratio Median Figure of 11 Publicly-Listed Commercial Services Companies 16.85x
Canada Market PE Ratio Median Figure of 556 Publicly-Listed Companies 15.29x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BIOREM.

TSXV:BRM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:BRM Share Price ÷ EPS (both in CAD)

= 0.4 ÷ 0.12

3.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIOREM is good value based on earnings compared to the CA Commercial Services industry average.
  • BIOREM is good value based on earnings compared to the Canada market.
Price based on expected Growth
Does BIOREM's expected growth come at a high price?
Raw Data
TSXV:BRM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 3.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-8.3%per year
North America Commercial Services Industry PEG Ratio Median Figure of 36 Publicly-Listed Commercial Services Companies 1.65x
Canada Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.21x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BIOREM, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BIOREM's assets?
Raw Data
TSXV:BRM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$0.33
TSXV:BRM Share Price * TSXV (2019-04-18) in CAD CA$0.4
Canada Commercial Services Industry PB Ratio Median Figure of 20 Publicly-Listed Commercial Services Companies 1.65x
Canada Market PB Ratio Median Figure of 2,377 Publicly-Listed Companies 1.51x
TSXV:BRM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:BRM Share Price ÷ Book Value per Share (both in CAD)

= 0.4 ÷ 0.33

1.2x

* Primary Listing of BIOREM.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIOREM is good value based on assets compared to the CA Commercial Services industry average.
X
Value checks
We assess BIOREM's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. BIOREM has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BIOREM expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover BIOREM, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BIOREM expected to grow at an attractive rate?
  • BIOREM's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 1.9%.
Growth vs Market Checks
  • BIOREM's earnings are expected to decrease over the next 1-3 years, this is below the Canada market average.
  • Unable to compare BIOREM's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:BRM Future Growth Rates Data Sources
Data Point Source Value (per year)
TSXV:BRM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -8.3%
Canada Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 60.6%
Canada Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 9.7%
Canada Market Earnings Growth Rate Market Cap Weighted Average 17.9%
Canada Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:BRM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:BRM Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 24 0 5
2018-09-30 22 1 1
2018-06-30 23 1 2
2018-03-31 23 1 1
2017-12-31 23 1 2
2017-09-30 19 1 1
2017-06-30 18 0 0
2017-03-31 15 2 0
2016-12-31 16 -1 1
2016-09-30 14 0 1
2016-06-30 15 1 1
2016-03-31 16 2 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BIOREM's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if BIOREM is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:BRM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BIOREM Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:BRM Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 0.12
2018-09-30 0.04
2018-06-30 0.04
2018-03-31 0.03
2017-12-31 0.04
2017-09-30 0.02
2017-06-30 0.01
2017-03-31 0.00
2016-12-31 0.04
2016-09-30 0.04
2016-06-30 0.05
2016-03-31 0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BIOREM will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BIOREM's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BIOREM has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BIOREM performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BIOREM's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BIOREM has delivered over 20% year on year earnings growth in the past 5 years.
  • BIOREM's 1-year earnings growth exceeds its 5-year average (204.9% vs 46.6%)
  • BIOREM's earnings growth has exceeded the CA Commercial Services industry average in the past year (204.9% vs 13.1%).
Earnings and Revenue History
BIOREM's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BIOREM Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:BRM Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 24.33 4.67 4.76 0.27
2018-09-30 22.00 1.38 4.18 0.31
2018-06-30 22.87 1.68 4.36 0.39
2018-03-31 23.36 1.34 4.40 0.40
2017-12-31 22.56 1.53 4.31 0.39
2017-09-30 18.78 0.54 4.13 0.40
2017-06-30 17.52 0.24 3.79 0.42
2017-03-31 14.79 0.19 3.51 0.41
2016-12-31 15.90 0.55 3.25 0.39
2016-09-30 14.45 0.53 3.09 0.39
2016-06-30 14.62 0.70 3.47 0.35
2016-03-31 16.38 1.53 3.61 0.40
2015-12-31 16.88 1.69 3.71 0.44
2015-09-30 17.54 1.57 3.86 0.48
2015-06-30 15.65 0.89 3.56 0.54
2015-03-31 13.40 -0.66 3.43 0.54
2014-12-31 10.68 -1.72 3.24 0.55
2014-09-30 11.84 -1.44 3.37 0.52
2014-06-30 14.83 -0.87 3.68 0.54
2014-03-31 17.38 0.22 3.85 0.56
2013-12-31 19.60 0.72 4.04 0.59
2013-09-30 18.86 0.82 3.44 0.75
2013-06-30 18.47 0.62 3.39 0.70
2013-03-31 16.34 -0.32 3.47 0.72
2012-12-31 15.42 -0.83 3.34 0.80
2012-09-30 14.48 -2.34 4.14 0.84
2012-06-30 10.55 -4.08 4.51 0.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BIOREM has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • BIOREM used its assets more efficiently than the CA Commercial Services industry average last year based on Return on Assets.
  • BIOREM's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess BIOREM's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BIOREM has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BIOREM's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BIOREM's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BIOREM is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BIOREM has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BIOREM's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BIOREM has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BIOREM Company Filings, last reported 3 months ago.

TSXV:BRM Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 12.90 0.00 3.95
2018-09-30 7.85 0.00 3.62
2018-06-30 7.68 0.00 3.66
2018-03-31 7.31 0.00 5.80
2017-12-31 7.30 0.00 3.57
2017-09-30 6.12 0.00 2.32
2017-06-30 5.69 0.00 2.42
2017-03-31 5.35 0.00 4.27
2016-12-31 2.43 2.17 1.12
2016-09-30 2.24 2.37 1.16
2016-06-30 2.16 2.55 1.75
2016-03-31 2.31 2.70 2.21
2015-12-31 1.93 2.87 2.73
2015-09-30 1.68 3.19 1.66
2015-06-30 1.00 3.50 2.03
2015-03-31 0.44 3.45 1.32
2014-12-31 -0.26 3.53 1.21
2014-09-30 -0.77 3.75 0.46
2014-06-30 -0.51 3.70 0.09
2014-03-31 0.44 3.62 0.63
2013-12-31 0.88 3.55 1.64
2013-09-30 0.60 3.45 0.68
2013-06-30 0.30 3.37 0.71
2013-03-31 0.03 3.29 0.96
2012-12-31 0.05 3.59 1.50
2012-09-30 -0.33 3.68 1.48
2012-06-30 -0.50 2.23 0.41
  • BIOREM has no debt.
  • BIOREM has no debt compared to 5 years ago when it was 403.4%.
  • BIOREM has no debt, it does not need to be covered by operating cash flow.
  • BIOREM has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess BIOREM's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BIOREM has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BIOREM's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BIOREM dividends.
If you bought CA$2,000 of BIOREM shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BIOREM's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BIOREM's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:BRM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 46 Stocks 1.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.4%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BIOREM has not reported any payouts.
  • Unable to verify if BIOREM's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BIOREM's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BIOREM has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BIOREM's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BIOREM afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BIOREM has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BIOREM's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Derek Webb
COMPENSATION CA$617,021
TENURE AS CEO 4.3 years
CEO Bio

Mr. Derek S. Webb, P.Eng., MBA has been the Chief Executive Officer and President of BIOREM Inc. since December 17, 2014. Mr. Webb served as Executive Vice President of BIOREM Inc. from January 2012 to December 17, 2014 and also served as its Vice President of Business Development. He serves as Director of BIOREM Inc. since December 17, 2014.

CEO Compensation
  • Derek's compensation has increased by more than 20% in the past year.
  • Derek's remuneration is higher than average for companies of similar size in Canada.
Management Team

Derek Webb

TITLE
CEO, President & Director
COMPENSATION
CA$617K
TENURE
4.3 yrs

Doug Newman

TITLE
CFO & Secretary
COMPENSATION
CA$354K
TENURE
7.1 yrs
Board of Directors Tenure

Average tenure of the BIOREM board of directors in years:

2.4
Average Tenure
  • The average tenure for the BIOREM board of directors is less than 3 years, this suggests a new board.
Board of Directors

Qingjie Zhao

TITLE
Chairman
COMPENSATION
CA$33K
AGE
60
TENURE
2.3 yrs

Derek Webb

TITLE
CEO, President & Director
COMPENSATION
CA$617K
TENURE
4.3 yrs

Brian Herner

TITLE
Director
COMPENSATION
CA$26K
TENURE
4.3 yrs

P. Ennis

TITLE
Director
COMPENSATION
CA$31K
TENURE
2.4 yrs

Sandy Ding

TITLE
Director
COMPENSATION
CA$24K
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess BIOREM's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BIOREM has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is BIOREM Inc. (CVE:BRM) A High Quality Stock To Own?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows BIOREM has a return on equity of 36% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

How Financially Strong Is BIOREM Inc. (CVE:BRM)?

However, the trade-off is BRM will have to follow strict debt obligations which will reduce its financial flexibility. … Zero-debt can alleviate some risk associated with the company meeting debt obligations, but this doesn’t automatically mean BRM has outstanding financial strength. … Is BRM growing fast enough to value financial flexibility over lower cost of capital

Simply Wall St -

How Should Investors React To BIOREM Inc.'s (CVE:BRM) CEO Pay?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … The aim of all this is to consider the appropriateness of CEO pay levels. … How Does Derek Webb's Compensation Compare With Similar Sized Companies?

Simply Wall St -

BIOREM Inc (CVE:BRM): A Look At Return On Capital

Your equity share is granted in return for the capital provided to the business to operate, and in order for an investment to be successful the business has to create earnings from the funds that make up this capital. … Your return is tied to BRM’s ability to do this because the amount earned is used to invest in opportunities to grow the business or payout dividends, which are the two sources of return on investment. … To understand BIOREM’s capital returns we will look at a useful metric called return on capital employed.

Simply Wall St -

Should You Expect BIOREM Inc (CVE:BRM) To Continue Delivering An ROE Of 18.4%?

and want to start learning about core concepts of fundamental analysis on practical examples from today's market. … This can be measured by looking at the company’s financial leverage. … Peeling the layers of ROE – trisecting a company’s profitability

Simply Wall St -

Is BIOREM Inc (CVE:BRM) Attractive At Its Current PE Ratio?

While this makes BRM appear like a great stock to buy, you might change your mind after I explain the assumptions behind the P/E ratio. … I will deconstruct the P/E ratio and highlight what you need to be careful of when using the P/E ratio … Breaking down the P/E ratio

Simply Wall St -

Can BIOREM Inc (CVE:BRM) Continue To Outperform Its Industry?

See our latest analysis for BIOREM Breaking down Return on Equity Return on Equity (ROE) is a measure of BIOREM’s profit relative to its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of BIOREM’s equity capital deployed. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity TSXV:BRM Last Perf Apr 13th 18 Basically, profit margin measures how much of revenue trickles down into earnings which illustrates how efficient the business is with its cost management.

Simply Wall St -

Company Info

Description

BIOREM Inc., an environmental biotechnology company, designs, manufactures, and sells air emissions control systems that are used to eliminate odors, volatile organic compounds, and hazardous air pollutants in Canada, the United States, China, and internationally. It offers biofilters for the removal of odors and hydrogen sulfide, as well as for the conditioning of biogas renewable energy, and for low air flow applications; and biotrickling filters for applications of high concentrations of H2S or other water soluble compounds. The company also provides multi-stage systems to treat odors associated with various municipal wastewater treatment processes; and biogas conditioning systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company is headquartered in Guelph, Canada.

Details
Name: BIOREM Inc.
BRM
Exchange: TSXV
Founded:
CA$15,464,623
38,661,558
Website: http://www.biorem.biz
Address: BIOREM Inc.
7496 Wellington Road 34,
Guelph,
Ontario, N1H 6H9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV BRM Common Shares TSX Venture Exchange CA CAD 21. Jan 2005
OTCPK BIRM.F Common Shares Pink Sheets LLC US USD 21. Jan 2005
Number of employees
Current staff
Staff numbers
0
BIOREM employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 23:57
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/03/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.